Nine Diagnostics was selected to present at the 2025 MIT Health Science Forum, hosted by the MIT Industrial Liaison Program (ILP) and MIT Startup Exchange. Held on May 8, 2025, the forum convened MIT researchers, global industry leaders, and select startups to showcase cutting-edge developments at the intersection of science, technology, and health. The event focused on five key […]
Nine Diagnostics, a leader in AI-enabled nanosensor technology, has been selected to participate in the American Cancer Society’s BrightEdge Entrepreneurs Program, a highly selective initiative designed to accelerate promising and high impact potential oncology-focused startups. This selection marks another significant milestone for Nine Diagnostics as it continues to drive innovation in cancer treatment selection, dosing, […]
“What we’d like to do is triage all gynaecological disease – so when someone comes in with a complaint, can we give doctors a tool that quickly tells them it’s more likely to be a cancer or not, or this cancer than that.” -Daniel Heller
Nine Diagnostics is proud to announce its acceptance into the latest cohort of the Merck Digital Sciences Studio (MDS Studio), a digital accelerator designed to enable the next generation of technologies for drug discovery and development, including artificial intelligence and machine learning. MDS Studio was founded to offer support for early-stage biomedical startups providing strategic […]
Nine Diagnostics, a leader in cutting-edge medical diagnostics, is honored to announce that it has been awarded the Novo Nordisk Golden Ticket for a residency at LabCentral, hosted by the Novo Nordisk Bio Innovation Hub. This incredible opportunity is a significant milestone for the company, reinforcing its commitment to improving healthcare through advanced technologies that […]
